Patent Application
20150133853
A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to any reproduction by anyone of the patent disclosure, as it appears in the United States Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.
The annual mortality rate for all lung diseases is estimated to be approximately 250,000 in the US in 2000. About 150,000 patients were related to acute, potentially reversible respiratory failure and 100,000 patients related to chronic respiratory failure due to chronic obstructive lung disease (COPD) or chronic irreversible respiratory failure due to other illness. The estimated economic burden of these diseases is in the range of 72 billion dollars per year. The rate of death related to COPD has increased by 54%, and the World Health Organization (WHO) estimated that COPD will affect 5-15% of all adults in industrialized countries and accounting for 3 million deaths worldwide in 2020, as the 5th most prevalent disease and the 3rd leading cause of mortality.
The primary purpose of this design is to replace the oxygenation function of the diseased lung during acute or chronic lung function and ventilatory impairment. Because the exchange rate of CO2 by the lungs is about 200 times more than that of oxygen, the oxygenation problem is the first and most serious clinical problem for us to face. Most of the clinical problems of CO2 retention can be solved simply by the patients themselves or by the mechanical ventilation to increase the minute ventilation. So we simply focus on the resolutions for the main problem of acute, moderate to severe hypoxemia and chronic respiratory failure with long-term hypoxemia. Due to the improvement of biomaterial, the possibility to use normal pressure to hyperbaric nano-sized pure oxygen bubbles to improve oxygenation of the intracaval deoxygenated hemoglobin is reachable. In patients with acute respiratory failure, the normal pressure to hyperbaric nano-bubbling intracaval oxygenator can replace the conventional mechanical ventilator, IVOX, IMO, and ECMO, to facilitate the oxygen demand of the patients. In patients of chronic respiratory failure, a low-flow intravenous oxygenator can replace conventional oxygen therapy system, improving the power and the motivation of patient activities.
The invention is directed at the intravascular nano-bubbling oxygenator that utilizes an intravascular catheter with numerous nano-porous surface, in order to facilitate oxygen bubbles binding with the deoxygenated hemoglobin of the red cells in cardiovascular system. The inventions were designed to improve the clinical hypoxic patients with any kinds of acute or chronic reasons.
The invention relates to the normal pressure to hyperbaric intravascular oxygenator, and more particularly to the different design of one lumen and multi lumens catheters with numerous nano-porous surface to facilitate nano-sized pure oxygen bubbles to the cardiovascular system.
Description of Related Arts
The primary purpose of the ventilation is to bring the air into and out the lungs, therefore oxygen can be added into the lungs and carbon dioxide can be removed. The volume of the pulmonary capillary circulation is about 150 ml, spreading over a surface area of approximately 750 square feet. This capillary surface area surrounds 300 million air sacs called alveoli. The deoxygenated venous return is oxygenated in less than one second in the pulmonary circulation due to huge capillary surface and extremely thin blood-alveolar barrier approximately one micrometer in distance. This allows the blood to be replenished with oxygen and for the excess carbon dioxide to be removed.
There have been numerous efforts in the past 40 years to achieve artificial ventilation function, such as negative pressure and positive pressure mechanical ventilator, and extracorporeal membrane oxygenator (ECMO).
Positive-pressure mechanical ventilation is a somewhat efficient and safe means for improving gas exchange in the patients with acute respiratory failure. However, serious adverse effects may occur with prolonged duration of intensive respiratory support or high oxygen fraction. These hazardous effects, including oxygen toxicity, barotraumas, altered hormone and enzyme systems, mechanical ventilation induced lung injury (VILI), disuse atrophy of skeleton muscles, and added to the morbidity and mortality rates for these patients.
Another approach to artificial lung function, extracorporeal membrane oxygenation (ECMO) constitutes a mechanism for prolonged pulmonary bypass, which has been developed and optimized over several decades but has limited clinical utility today as a state-of-the-art artificial lung. The ECMO system includes an extra-corporeal pump and membrane system that performs a gas transfer across membranes. Despite the numerous advances in the implementation of ECMO over the years, its core technology is unchanged and continues to face important limitations. The limitations of ECMO include the requirement for a large and complex blood pump and oxygenator system, the necessity for a surgical procedure for cannulation, the need for systemic anticoagulation, the labor intensive implementation, the exceeding high cost, and a high rate of complications, including bleeding and infection, protein absorption, and platelet adhesion on the surface of the oxygenator membrane. As a result of these limitations, the ECMO has become limited in its utility to select cases of neonatal respiratory failure, where reversibility is considered to be highly likely.
One approach to artificial lung functions has been by gas sparing or diffusion of gas across the membrane surface of hollow fibers placed within the blood supply. Previous efforts have achieved some success, and have taught much to pulmonary physiologists, but gas sparing or diffusion has not yet achieved the degree of gas exchanges optimally desired. The development of the intravenous membrane oxygenator (IVOX) presented a natural extension in the artificial lung art, since it was capable of performing intracorporeal gas exchange across an array of hollow fiber membranes situated within the inferior vena cava but did not require any form of blood pump. The insertion of the IVOX effectively introduced a large amount of gas transfer surface area (up to 600 cm2) without alternation of systemic hemodynamics; unfortunately, as with ECMO, the IVOX system has numerous limitations including a moderate rate of achievable gas exchange, difficulty in device implantation, a relatively high rate of adverse events, and a significant rate of device malfunctions, including blood-to-gas leaks due to broken hollow fibers.
Clinically, there is still a long way to go for us to achieve perfect artificial oxygenation whether in acute patients or long-term care. Therefore, a serious need exists for new technology and therapeutic approaches that have the potential to provide acute, intermediate to chronic, and long-term respiratory support for patients suffering from severe pulmonary failure. There also remains a paramount need for an efficient and inexpensive technology to achieve sustained oxygen concentration in the blood, thereby bypassing the diseased lung without resorting to further damage.
The present invention is to provide a normal pressure to hyperbaric nano-bubbling intravascular oxygenation system comprising a catheter with single or multiple lumens, a tube wall with numerous nano-sized pores on its surface, capable of being inserted into a blood vessel to transport gas.
Referring to
The catheter 110 includes one closed end and one opening end. The opening end is connected to a connector 120.
The connector 120 connects the catheter 110 and the gas transporting apparatus 130. The gas transporting apparatus 130 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 120. The gas transporting apparatus 130 comprises a flow adjustor 131 with a flow sensor (not shown), a pressure adjustor 132 with a barometer (not shown), a thermo adjustor 133 with a thermometer (not shown) for these range parameters.
A pipe 140 connects the gas transporting apparatus 130 and a high pressure gas tank or any other container 142 with a regulator 141. In an embodiment, the gas is oxygen. The regulator 141 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator. The thermo adjustor 133 warms or cools the oxygen to a proper temperature, the pressure adjuster 132 adjusts the pressure of the oxygen, and the flow adjustor 131 controls the flow rate of the oxygen. The oxygen passes the connector 120 to the tube 110, and then distributes through the pores 112 to the blood. The pores 112 help produce bubbles in a range of nanometer to micrometer scale for range parameters when transporting gas.
The control panel 150 calculates the feedback of the measurement of the blood oxygen concentration, vena caval pressure, heart rate, and temperature by one or one more detectors (not shown) and controls the gas transporting apparatus 130 for transporting gas at the specific range of temperature, pressure, and flowrate to the catheter 110 through the connector 120.
Referring to
The connector 220 connects the gas lumen 215 of the catheter 210 and the gas transporting apparatus 230. The gas transporting apparatus 230 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 220. The gas transporting apparatus 230 comprises a flow adjustor 231 with a flow sensor (not shown), a pressure adjustor 232 with a barometer (not shown), a thermo adjustor 233 with a thermometer (not shown) for range parameters.
A pipe 240 connects the gas transporting apparatus 230 and a high pressure gas tank or any other container 242 with a regulator 241. In an embodiment, the gas is oxygen. The regulator 241 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator. The thermo adjustor 233 warms or cools the oxygen to a proper temperature, the pressure adjuster 232 adjusts the pressure of the oxygen, and the flow adjustor 231 controls the flow rate of the oxygen for range parameters. The oxygen passes the connector 220 to the gas lumen 215 of the catheter 210, and then distributes through the pores 212 to the blood. The pores 212 help produce bubbles in a range of nanometer to micrometer scale when transporting gas.
The control panel 250 calculates the feedback of the measurement of the blood oxygen concentration, vena caval pressure, heart rate, or temperature by one or one more detectors (not shown) and controls the gas transporting apparatus 230 for transporting gas at the specific range of temperature, pressure, and flowrate to the gas lumen 215 of the catheter 210 through the connector 220.
Referring to
One skilled in the art will understand that the embodiment of the present invention as shown in the drawings and described above is exemplary only and not intended to be limiting.
The foregoing description of the preferred embodiment of the present invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form or to exemplary embodiments disclosed. Accordingly, the foregoing description should be regarded as illustrative rather than restrictive. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. The embodiments are chosen and described in order to best explain the principles of the invention and its best mode practical application, thereby to enable persons skilled in the art to understand the invention for various embodiments and with various modifications as are suited to the particular use or implementation contemplated. It is intended that the scope of the invention be defined by the claims appended hereto and their equivalents in which all terms are meant in their broadest reasonable sense unless otherwise indicated. It should be appreciated that variations may be made in the embodiments described by persons skilled in the art without departing from the scope of the present invention as defined by the following claims. Moreover, no element and component in the present disclosure is intended to be dedicated to the public regardless of whether the element or component is explicitly recited in the following claims.
This is a Continuation application that claims priority to U.S. non-provisional application, application Ser. No. 11/868,528, filed Oct. 7, 2007, the entire contents of each of which are expressly incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11868528 | Oct 2007 | US |
| Child | 14602260 | US |
